Hikomicron

Hikomicron is a topical medication that contains hydrocortisone as its active ingredient. Marketed in the European Union, it is formulated for skin application at a standard dermatological strength. As a corticosteroid, it is intended to reduce inflammation and allergic responses when applied to affected areas for short‑term use. The product is supplied without a specific brand suffix and is classified under anti‑inflammatory and antiallergic therapy.

Hikomicron is indicated for a range of inflammatory and allergic skin conditions where topical corticosteroid therapy is appropriate.

- Mild to moderate eczema (atopic dermatitis) affecting the face, limbs, or trunk. - Contact dermatitis caused by irritants or allergens. - Seborrheic dermatitis on scalp or facial areas. - Psoriasis plaques that respond to low‑potency corticosteroids. - Insect bite reactions with localized swelling and redness. - Minor skin irritations such as rash or sunburn where inflammation control is desired.

Topical hydrocortisone may cause local or systemic adverse reactions, although many users experience no problems.

Common: - Mild skin irritation or burning sensation at the application site. - Pruritus or itching that may persist despite treatment. - Dryness or peeling of the treated skin. - Slight erythema or redness beyond the target area.

Serious: - Signs of skin atrophy such as thinning, bruising, or visible blood vessels. - Development of contact dermatitis or allergic reaction to the formulation. - Systemic corticosteroid effects including adrenal suppression with extensive use. - Secondary infection of the skin, including bacterial, fungal, or viral overgrowth.

Before using Hikomicron, consider the following precautions to minimize risks and ensure appropriate therapy.

- Avoid application on broken, infected, or ulcerated skin unless directed by a healthcare professional. - Limit use to the prescribed area and duration; prolonged or widespread use can increase systemic absorption. - Do not apply under occlusive dressings unless specifically instructed. - Use caution in infants, young children, or patients with a history of skin thinning. - Review pregnancy or breastfeeding status with a clinician, as safety data are limited. - Discontinue and seek medical advice if signs of allergic reaction or worsening skin condition occur.

Hydrocortisone can interact with other topical or systemic agents; be aware of the following potential interactions.

Avoid: - Concurrent use of other potent topical corticosteroids on the same area, which may increase the risk of skin atrophy. - Application of topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) on overlapping sites, as combined immunosuppression may occur.

Use with caution: - Systemic corticosteroids, which can augment systemic effects when large skin areas are treated. - Antifungal or antibacterial creams that may alter skin barrier and affect absorption. - Phototherapy or UV exposure, which can increase skin sensitivity when combined with corticosteroids.